Analysts expect Dianthus Therapeutics, Inc. /DE/ to report revenue of 420,052.98 for Q3 26, against a range of 378,130.01 to 461,975.95. The most recent reported quarter, Q2 26, came in at 761,000.00, a 166.9% beat against the 285,074.37 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 2.17 M | 1.32 M | 1.16 M | 193,000.00 | 396,000.00 | 284,000.00 | 463,000.00 | 761,000.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 736,337.73 | 970,370.37 | 803,820.63 | 990,201.70 | 642,001.28 | 604,013.88 | 467,287.28 | 303,446.56 | 461,975.95 | 376,181.20 | 440,275.33 | 417,227.60 | 266,711.49 | 98,962.81 | 3.42 M | 3.93 M | ||||||||||
| Low Estimate | 676,667.91 | 878,658.53 | 718,307.47 | 827,586.04 | 570,801.28 | 530,321.76 | 384,141.04 | 266,702.18 | 378,130.01 | 308,643.14 | 389,094.89 | 371,868.76 | 233,415.53 | 85,844.27 | 3.11 M | 3.57 M | ||||||||||
| Consensus Estimate | 706,502.82 | 924,514.45 | 761,064.05 | 908,893.87 | 606,401.28 | 567,167.82 | 425,714.16 | 285,074.37 | 420,052.98 | 342,412.17 | 414,685.11 | 394,548.18 | 250,063.51 | 92,403.54 | 3.26 M | 3.75 M |
Analysts expect Dianthus Therapeutics, Inc. /DE/ to report earnings per share of -0.98 for Q3 26, against a range of -1.04 to -0.92. The most recent reported quarter, Q2 26, came in at -0.90, a 8.4% miss against the -0.83 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.74 | -0.81 | -0.82 | -0.88 | -0.97 | -1.43 | -0.85 | -0.90 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.52 | -0.80 | -0.85 | -0.77 | -0.76 | -0.99 | -1.00 | -0.75 | -0.92 | -0.96 | -1.06 | -0.98 | -1.11 | -1.23 | -1.30 | -1.26 | ||||||||||
| Low Estimate | -0.62 | -0.86 | -0.97 | -0.89 | -0.88 | -1.13 | -1.20 | -0.91 | -1.04 | -1.10 | -1.24 | -1.10 | -1.31 | -1.47 | -1.40 | -1.40 | ||||||||||
| Consensus Estimate | -0.57 | -0.83 | -0.91 | -0.83 | -0.82 | -1.06 | -1.10 | -0.83 | -0.98 | -1.03 | -1.15 | -1.04 | -1.21 | -1.35 | -1.35 | -1.33 |
Pull Wall Street consensus for Dianthus Therapeutics, Inc. /DE/ (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=DNTH&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "DNTH", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=DNTH&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();